Changes in Hong Kong stocks | Jingfang Pharmaceutical-B (02595) rose nearly 4% in the afternoon. Oral KRAS G12D inhibitors revealed excellent clinical data

Zhitongcaijing · 1d ago

The Zhitong Finance App learned that Jinfang Pharmaceutical-B (02595) rose nearly 4% in the afternoon. As of press release, it rose 3.57% to HK$30.76, with a turnover of HK$93.7925 million.

According to the news, recently, Jinfang Pharmaceutical/Verastem Oncology revealed that several domestic and overseas clinical studies of the oral KRAS G12D inhibitor GFH375/VS-7375 have made positive progress and released the latest data on related studies, showing good efficacy and safety.

CITIC Construction Investment released a research report stating that based on the promotion of GFH375 registration phase III and the expansion of multiple indications and frontline combination treatment, combined with the clinical potential of GFH276, GFS202A and GFS784 pipeline layout, and overseas development and cooperation, the clinical and commercial prospects of the company's core products are expected to be clear, providing support for medium- to long-term development.